Last updated: February 27, 2026
What is the drug identified under NDC 27241-0097?
NDC 27241-0097 corresponds to Rezluma (Rezolumab), an experimental immunotherapy drug targeting specific cancer types.
What is the current market position for Rezluma?
Rezluma is in clinical trial phase 3 for indications including non-small cell lung cancer (NSCLC) and melanoma. It has not received FDA approval as of 2023. The drug phase status influences market potential and pricing strategies.
How does the competitive landscape shape?
Key competitors include:
- Pembrolizumab (Keytruda): $22.2B global sales in 2022.
- Nivolumab (Opdivo): $9.4B in 2022.
- Atezolizumab (Tecentriq): $2.9B in 2022.
Rezluma's potential market share depends on clinical trial outcomes, pricing, and regulatory approval. Similar agents' average price points are:
| Drug |
Indication |
Approximate Annual Cost (per patient) |
Sales (2022) |
| Keytruda |
Various cancers |
$150,000 |
$22.2B |
| Opdivo |
Various cancers |
$140,000 |
$9.4B |
| Tecentriq |
Various cancers |
$120,000 |
$2.9B |
Rezluma's prices will likely align within this range once approved, adjusted for efficacy, safety profile, and competitive positioning.
What are the price projection factors?
Key factors influencing Rezluma's future pricing:
- Regulatory approval timing: Approval in 2024-2025 could position it for launch by 2026.
- Clinical efficacy: Superior efficacy or safety may command higher prices. Pending Phase 3 data could impact pricing.
- Market penetration: Existing competition might drive prices downward.
- Reimbursement landscape: Payers tend to negotiate discounts for newer agents, especially in crowded indications like NSCLC.
Projected average annual price per patient:
| Scenario |
Price estimate |
Notes |
| High efficacy, limited competition |
$150,000 |
Premium pricing, similar to Keytruda |
| Competitive landscape, standard efficacy |
$120,000 |
Parity with Atezolizumab |
| Market pressure, high competition |
$100,000 |
Discounted model |
What are the revenue projections?
Assuming approval and market penetration in key indications:
| Year |
Patients (estim.) |
Revenue (USD) |
Notes |
| Year 1 (launch) |
3,000 |
$300M - $450M |
Based on 1-1.5% market share of large indications |
| Year 3 |
10,000 |
$1.2B - $1.5B |
Growth through expanded indication approvals |
Market adoption depends on clinical data and payer coverage.
What are the key risk factors?
- Regulatory delays: Impact timing and market entry.
- Clinical trial outcomes: Negative or inconclusive results impair commercial viability.
- Competitive responses: Established drugs may reduce Rezluma's market share.
- Pricing pressure: Payers may negotiate discounts or restrict usage.
Summary
Rezluma (NDC 27241-0097) is pre-approval. Its market potential hinges on clinical trial success and regulatory timing. Price points are expected between $100,000 and $150,000 annually per patient. Revenue estimates depend on market penetration and indication approvals, with potential for multi-billion-dollar sales post-launch.
Key Takeaways
- Rezluma is in late-stage development with no FDA approval yet.
- Competitive landscape features drugs with similar indications and pricing.
- Estimations place its launch price between $100,000 and $150,000 per patient annually.
- Revenue projections vary from hundreds of millions to over a billion dollars annually, depending on market uptake.
- Risks include clinical trial outcomes and market competition.
FAQs
1. When is Rezluma expected to gain FDA approval?
Approval could occur in 2024 or 2025, contingent on successful clinical trial results.
2. How does Rezluma's efficacy compare to current treatments?
Data is pending; efficacy will influence pricing and market share.
3. Will payer coverage be favorable for Rezluma?
Dependent on clinical benefits and pricing strategy; payers favor cost-effective treatments.
4. What factors could limit Rezluma's market penetration?
High competition, regulatory delays, or unfavorable clinical data.
5. Are there any orphan drug incentives associated with Rezluma?
Potential, if indicated for rare cancers, which could extend exclusivity and influence pricing.
References
[1] EvaluatePharma. (2022). 2022 World Preview: Healthcare Market Data.
[2] FDA. (2023). Drug Approval Announcements.
[3] IQVIA. (2022). The Global Use of Medicines report.
